Virus-gene interactions during hepatic carcinogenesis

肝癌发生过程中病毒与基因的相互作用

基本信息

  • 批准号:
    8331461
  • 负责人:
  • 金额:
    $ 20.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-12 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC is a type of malignancy whose pathogenesis is induced by a combination of genetic and environmental factors. Among the environmental factors, HBV or HCV infections are the major risk factors. Recent molecular and genetic studies have demonstrated that HBV and HCV viral proteins have direct roles during HCC pathogenesis by de-regulating signaling pathways important for hepatocyte proliferation, differentiation and apoptosis.15 However, the long latency and low incidence rate of HCC development from the HBV or HCV transgenic mice studies suggest that additional genetic mutations occur in these damaged hepatocytes, which are required for the malignant transformation and HCC formation. The goal of the proposal is to characterize the virus-gene interactions during hepatic carcinogenesis. We hypothesize that specific genetic events, such as c-Myc or c-Met overexpression, ¿-catenin activating mutations, and loss of tumor suppressor genes TP53, will accelerate HCC development in HBV or HCV core transgenic mice. To test the hypothesis, we propose two Specific Aims. In Aim One, we will determine the genetic alteration(s) that induces hepatic carcinogenesis in HBV transgenic mice; and in Aim Two, we will determine the genetic alteration(s) that induces hepatic carcinogenesis in HCV Core transgenic mice. To achieve these aims, we will apply hydrodynamic transfection method to directly target genes (using either expression vectors or shRNA constructs) into mouse hepatocytes for long term and stable expression. The genes that we plan to express into HBV or HCV core transgenic mice include: c-Myc, c-Met, N90-2-catenin and sh-p53, all representing common genetic modifications observed during human HCC pathogenesis. By expressing these specific genes into the mouse liver, we will determine whether any of these genetic alterations is able to accelerate HCC development when mice are predisposed to hepatic carcinogenesis induced by HBV entire genome or HCV core protein expression. Altogether, the proposed studies will be of great help in identifying important driver oncogenes or tumor suppressor genes that have critical roles during liver cancer pathogenesis. The study will also provide novel insight into the molecular mechanisms of HCC development in the context of viral oncoprotein expression. The murine models generated from the proposed study will significantly benefit HCC research community and provide valuable in vivo models to study novel strategies for HCC prevention and treatment.
描述(由申请人提供):肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一。HCC是一种恶性肿瘤,其发病机制是由遗传和环境因素共同诱导的。在环境因素中,HBV或HCV感染是主要的危险因素。最近的分子和遗传学研究表明,HBV和HCV病毒蛋白通过去调节肝细胞增殖、分化和凋亡的重要信号通路,在HCC发病过程中起直接作用然而,从HBV或HCV转基因小鼠研究中发现的HCC发展的长潜伏期和低发生率表明,这些受损的肝细胞中发生了额外的基因突变,这是恶性转化和HCC形成所必需的。该建议的目的是表征肝癌发生过程中的病毒-基因相互作用。我们假设特定的遗传事件,如c-Myc或c-Met过表达、-catenin激活突变和肿瘤抑制基因TP53的缺失,将加速HBV或HCV核心转基因小鼠的HCC发展。为了验证这一假设,我们提出了两个具体目标。在目的一中,我们将确定在HBV转基因小鼠中诱导肝癌发生的基因改变;在第二阶段,我们将确定在HCV Core转基因小鼠中诱导肝癌发生的基因改变。为了实现这些目标,我们将采用水动力转染方法将目标基因(使用表达载体或shRNA构建物)直接导入小鼠肝细胞中进行长期稳定表达。我们计划在HBV或HCV核心转基因小鼠中表达的基因包括:c-Myc、c-Met、N90-2-catenin和sh-p53,这些基因都是在人类HCC发病过程中观察到的常见基因修饰。通过在小鼠肝脏中表达这些特定基因,我们将确定当小鼠易受HBV全基因组或HCV核心蛋白表达诱导的肝癌发生时,这些基因改变是否能够加速HCC的发展。总之,这些研究将有助于发现在肝癌发病过程中起关键作用的重要驱动癌基因或肿瘤抑制基因。该研究还将为在病毒癌蛋白表达背景下HCC发展的分子机制提供新的见解。本研究建立的小鼠模型将极大地造福于HCC研究界,并为研究HCC预防和治疗的新策略提供有价值的体内模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xin Chen其他文献

Xin Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xin Chen', 18)}}的其他基金

Investigating multifactorial beta-catenin activation in hepatocellular cancers
研究肝细胞癌中的多因素 β-连环蛋白激活
  • 批准号:
    10541171
  • 财政年份:
    2022
  • 资助金额:
    $ 20.16万
  • 项目类别:
Investigating multifactorial beta-catenin activation in hepatocellular cancers
研究肝细胞癌中的多因素 β-连环蛋白激活
  • 批准号:
    10574374
  • 财政年份:
    2022
  • 资助金额:
    $ 20.16万
  • 项目类别:
Signaling pathways during hepatocarcinogenesis
肝癌发生过程中的信号通路
  • 批准号:
    10636858
  • 财政年份:
    2022
  • 资助金额:
    $ 20.16万
  • 项目类别:
Signaling pathways during hepatocarcinogenesis
肝癌发生过程中的信号通路
  • 批准号:
    10570081
  • 财政年份:
    2022
  • 资助金额:
    $ 20.16万
  • 项目类别:
Investigating multifactorial beta-catenin activation in hepatocellular cancers
研究肝细胞癌中的多因素 β-连环蛋白激活
  • 批准号:
    10326862
  • 财政年份:
    2021
  • 资助金额:
    $ 20.16万
  • 项目类别:
Cabozentinib based combination therapy for the treatment of hepatocellular carcinoma
基于卡博替尼的联合疗法治疗肝细胞癌
  • 批准号:
    10117217
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
Signaling pathways during hepatocarcinogenesis
肝癌发生过程中的信号通路
  • 批准号:
    9906655
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
癌症相关成纤维细胞在胆管癌中的作用
  • 批准号:
    10166796
  • 财政年份:
    2018
  • 资助金额:
    $ 20.16万
  • 项目类别:
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
癌症相关成纤维细胞在胆管癌中的作用
  • 批准号:
    10414782
  • 财政年份:
    2018
  • 资助金额:
    $ 20.16万
  • 项目类别:
Inducible systems for studying liver tumor mainenance in vivo
用于研究肝脏肿瘤体内维持的诱导系统
  • 批准号:
    9457376
  • 财政年份:
    2017
  • 资助金额:
    $ 20.16万
  • 项目类别:

相似海外基金

Uncovering colorectal cancer etiology and biology by integrating proteomics with other omics data
通过将蛋白质组学与其他组学数据相结合,揭示结直肠癌的病因学和生物学
  • 批准号:
    10585424
  • 财政年份:
    2023
  • 资助金额:
    $ 20.16万
  • 项目类别:
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and Europeans
发现因果蛋白标记物以提高非洲人和欧洲人对前列腺癌病因的了解和风险预测
  • 批准号:
    10446594
  • 财政年份:
    2022
  • 资助金额:
    $ 20.16万
  • 项目类别:
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and Europeans
发现因果蛋白标记物以提高非洲人和欧洲人对前列腺癌病因的了解和风险预测
  • 批准号:
    10647719
  • 财政年份:
    2022
  • 资助金额:
    $ 20.16万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10307055
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
Uncovering Roles of Metabolites in Colorectal Cancer Etiology
揭示代谢物在结直肠癌病因学中的作用
  • 批准号:
    10224955
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
Uncovering Roles of Metabolites in Colorectal Cancer Etiology
揭示代谢物在结直肠癌病因学中的作用
  • 批准号:
    10201868
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10527364
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
Life course body fatness and physical activity, and ovarian cancer etiology
生命历程身体脂肪和体力活动以及卵巢癌病因
  • 批准号:
    435914
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
    Operating Grants
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10093129
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    9885673
  • 财政年份:
    2020
  • 资助金额:
    $ 20.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了